A groundbreaking research initiative spearheaded by the University of Strathclyde will investigate the transformative role of artificial intelligence (AI) and machine learning in the creation and production of mRNA-based vaccines and therapies. With support exceeding £440,000 from Innovate UK, this endeavor aims to enhance the timelines associated with genomic medicine, concentrating on genetic research for developing vaccines and treatments for cancer, rare diseases, and other health issues. 

The study will focus on lipid-based nanoparticles designed to carry ribonucleic acid (RNA) for effective delivery into human cells. RNA is essential for all living organisms, assisting the body in creating new cells and responding to immune challenges. Specifically, messenger RNA (mRNA) offers genetic instructions that aid the body in generating cells needed for immune responses, particularly regarding vaccines. 

This cutting-edge project is led by Micropore Technologies, a drug formulation and manufacturing firm situated in Redcar, and involves collaboration with the Universities of Northumbria, Teesside, and Strathclyde. Together, they aim to overcome one of the most challenging phases in creating genomic medicines—the encapsulation of nucleic acids within protective nanoparticles. 

Professor Yvonne Perrie, the Head of the Strathclyde Institute of Pharmacy and Biomedical Sciences, highlighted the potential for transformative change brought by this research. “This work could significantly alter how genomic medicines are designed and produced. By utilizing machine learning in these intricate processes, we aspire to make substantial progress in enhancing the speed and efficacy of delivering these treatments to patients,” she noted. “We are thrilled to be part of this collaboration, particularly in the area of nanoparticle testing.” 

The project aims to overcome the difficulties inherent in the existing methods for formulating genomic medicines. Professor Wai Lok Woo, Chair in Machine Learning at Northumbria University, elaborated, “The process of encapsulating nucleic acids within nanoparticles is a vital stage, and the current techniques are time-consuming and iterative. This research will employ machine learning to comprehend the interactions in this process and fast-track formulation development, significantly boosting the efficiency of creating genomic medicines.” 

Micropore Technologies, recognized for its Advanced Crossflow technology, will integrate machine learning models alongside academic partners to refine the drug formulation process. Dave Palmer, Technical Manager at Micropore Technologies, shared his excitement about the project, stating, “We are looking forward to collaborating with our partners to leverage machine learning, streamlining the initial phases of laboratory-scale development and enhancing manufacturing processes. This will enable us to introduce new genomic medicines to the market more rapidly.” 

This collaboration highlights the University of Strathclyde’s dedication to promoting health innovation and collaborating closely with both academic institutions and industry leaders to tackle significant challenges in contemporary medicine. As the project advances, it has the potential to transform the landscape of genomic medicine and expedite the availability of advanced treatments for various diseases.